Skip to main content
Premium Trial:

Request an Annual Quote

Facing Nasdaq Delisting, Hybridon Plans One-for-Five Reverse Stock Split

Premium

CAMBRIDGE, Mass.--Hybridon, a genetically based drug discovery company here, has filed with the US Securities and Exchange Commission for a one-for-five reverse stock split, which would shrink the company's outstanding shares from about 25 million to 5 million. The plan, which will be presented to shareholders at a special meeting November 18, was proposed to help the company continue to meet Nasdaq listing requirements.

Last month, the exchange notified Hybridon of impending delisting, however, the company has appealed and its stock continues to be traded pending the outcome. Hybridon has expressed concern that delisting could adversely affect its liquidity and ability to raise capital.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.